Sol-Gel Technologies Ltd (SLGL)

$55.68 +2.44 (4.58%)
Market Cap 148.32M
Revenue (ttm) 11.54M
Net Income (ttm) -10.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -91.68%
Debt to Equity Ratio 0.00
Volume 14,100
Avg Vol 19,118
Day's Range N/A - N/A
Shares Out 2.79M
Stochastic %K 98%
Beta 1.35
Analysts Sell
Price Target $50.00

Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 931 3433
Address:
7 Golda Meir Street, Weizmann Science Park, Ness Ziona, Israel
weichsel1
weichsel1 Jan. 8 at 4:12 PM
$SLGL There is actual stable trading at this new higher price level - not just a blip of bid / ask flux.
0 · Reply
DarkSonar
DarkSonar Jan. 7 at 11:23 PM
$SLGL Remember two years ago there was this gentleman here buying up these shares and he was the only person talking about this stock (I was here trying to get a position) and he talked about the future of this stock. It went parabolic. They reversed split and now is $53.00. I think he was loading up at $0.60s My hats off to him if he’s still here. 💎
1 · Reply
kshonstocks
kshonstocks Jan. 7 at 6:56 PM
$SLGL 99 rs name https://research.investors.com/stock-quotes/nasdaq-solgel-technologies-slgl.htm
0 · Reply
GianniCisnerosVp
GianniCisnerosVp Jan. 7 at 5:45 AM
$SLGL thin tape biotech vibe, coil is tight, volume igniti
0 · Reply
weichsel1
weichsel1 Jan. 1 at 3:24 AM
$SLGL up 10 percent after hours? Is someone playing with the year closing price?
1 · Reply
JewelerJest
JewelerJest Dec. 27 at 11:56 AM
$SLGL Short‑term swings mask the deeper question: can discipline hold; customer retention trends will be critical to monitor — execution across cycles would support multiple expansion. The thesis tightens only when delivery matches ambition.
0 · Reply
TARPTrader
TARPTrader Dec. 25 at 10:20 AM
$SLGL Market tolerance narrows as uncertainty lingers, with macro volatility magnifying operational missteps. Measured progress can gradually rebuild conviction.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 1:09 AM
$SLGL
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 11:23 AM
HC Wainwright & Co. has updated their rating for Sol-Gel Technologies ( $SLGL ) to Buy with a price target of 50.
0 · Reply
weichsel1
weichsel1 Dec. 17 at 4:53 PM
$SLGL Quite surprised that the stock price did not drop more in light of the news on termination of its secondary drug in development. This leaves on the primary in progress: https://finance.yahoo.com/news/sol-gel-provides-following-unblinding-120000499.html
0 · Reply
Latest News on SLGL
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 20, 2025, 7:30 AM EST - 7 weeks ago

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 15, 2025, 7:00 AM EDT - 5 months ago

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025, 7:15 AM EDT - 8 months ago

Sol-Gel Reports First Quarter 2025 Results

Sol-Gel Announces Reverse Share Split

May 1, 2025, 7:00 AM EDT - 9 months ago

Sol-Gel Announces Reverse Share Split

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Apr 17, 2025, 8:40 AM EDT - 9 months ago

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

Apr 7, 2025, 10:01 AM EDT - 9 months ago

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 15, 2024, 7:00 AM EST - 1 year ago

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 17, 2024, 11:27 AM EDT - 1 year ago

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 16, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Technologies Announces Management Realignment

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Technologies Announces Management Realignment

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 20, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

May 16, 2024, 6:00 AM EDT - 1 year ago

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Nov 30, 2023, 7:00 AM EST - 2 years ago

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Nov 28, 2023, 8:06 AM EST - 2 years ago

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Jun 6, 2023, 7:30 AM EDT - 2 years ago

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 7:00 AM EDT - 2 years ago

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Mar 20, 2023, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Mar 10, 2023, 7:00 AM EST - 3 years ago

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Jan 27, 2023, 7:29 AM EST - 3 years ago

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Jan 27, 2023, 7:00 AM EST - 3 years ago

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 10, 2022, 4:00 AM EST - 3 years ago

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Oct 3, 2022, 8:00 AM EDT - 3 years ago

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 6:00 AM EDT - 3 years ago

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 13, 2022, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Apr 25, 2022, 7:00 AM EDT - 4 years ago

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Apr 14, 2022, 8:30 AM EDT - 4 years ago

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Mar 30, 2022, 7:00 AM EDT - 4 years ago

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Mar 25, 2022, 11:00 AM EDT - 4 years ago

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Dec 22, 2021, 4:05 PM EST - 4 years ago

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Dec 21, 2021, 7:00 AM EST - 4 years ago

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Nov 11, 2021, 7:00 AM EST - 4 years ago

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Nov 9, 2021, 7:05 AM EST - 4 years ago

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sep 22, 2021, 7:30 AM EDT - 4 years ago

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Sep 9, 2021, 8:30 AM EDT - 4 years ago

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Aug 4, 2021, 7:05 AM EDT - 4 years ago

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

Jul 27, 2021, 10:26 AM EDT - 4 years ago

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Jul 27, 2021, 9:15 AM EDT - 4 years ago

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Jul 20, 2021, 7:05 AM EDT - 4 years ago

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Sol-Gel Announces Pipeline Update and Future Development Plans

Jun 28, 2021, 5:10 AM EDT - 4 years ago

Sol-Gel Announces Pipeline Update and Future Development Plans

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Jun 28, 2021, 5:00 AM EDT - 4 years ago

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

May 13, 2021, 7:05 AM EDT - 5 years ago

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

Apr 27, 2021, 12:03 PM EDT - 5 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX CYCN

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

Apr 27, 2021, 10:02 AM EDT - 5 years ago

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update

Mar 4, 2021, 7:05 AM EST - 5 years ago

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update

weichsel1
weichsel1 Jan. 8 at 4:12 PM
$SLGL There is actual stable trading at this new higher price level - not just a blip of bid / ask flux.
0 · Reply
DarkSonar
DarkSonar Jan. 7 at 11:23 PM
$SLGL Remember two years ago there was this gentleman here buying up these shares and he was the only person talking about this stock (I was here trying to get a position) and he talked about the future of this stock. It went parabolic. They reversed split and now is $53.00. I think he was loading up at $0.60s My hats off to him if he’s still here. 💎
1 · Reply
kshonstocks
kshonstocks Jan. 7 at 6:56 PM
$SLGL 99 rs name https://research.investors.com/stock-quotes/nasdaq-solgel-technologies-slgl.htm
0 · Reply
GianniCisnerosVp
GianniCisnerosVp Jan. 7 at 5:45 AM
$SLGL thin tape biotech vibe, coil is tight, volume igniti
0 · Reply
weichsel1
weichsel1 Jan. 1 at 3:24 AM
$SLGL up 10 percent after hours? Is someone playing with the year closing price?
1 · Reply
JewelerJest
JewelerJest Dec. 27 at 11:56 AM
$SLGL Short‑term swings mask the deeper question: can discipline hold; customer retention trends will be critical to monitor — execution across cycles would support multiple expansion. The thesis tightens only when delivery matches ambition.
0 · Reply
TARPTrader
TARPTrader Dec. 25 at 10:20 AM
$SLGL Market tolerance narrows as uncertainty lingers, with macro volatility magnifying operational missteps. Measured progress can gradually rebuild conviction.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 1:09 AM
$SLGL
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 11:23 AM
HC Wainwright & Co. has updated their rating for Sol-Gel Technologies ( $SLGL ) to Buy with a price target of 50.
0 · Reply
weichsel1
weichsel1 Dec. 17 at 4:53 PM
$SLGL Quite surprised that the stock price did not drop more in light of the news on termination of its secondary drug in development. This leaves on the primary in progress: https://finance.yahoo.com/news/sol-gel-provides-following-unblinding-120000499.html
0 · Reply
JohnTrack
JohnTrack Dec. 17 at 2:52 PM
$SLGL watching for strength to show
0 · Reply
JohnTrack
JohnTrack Dec. 17 at 1:49 PM
$SLGL quick update... https://www.rapidticker.com/news/slgl-sec-filing-a22463
0 · Reply
weichsel1
weichsel1 Dec. 1 at 6:16 PM
$SLGL 35 to 45 with5 trading days and now almost back again. Talk about volatility.
0 · Reply
aletz
aletz Nov. 24 at 9:57 PM
$SLGL https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk4/ SLGL was selected #3 on this week's AI scanner result and already showing strong momentum. MIST and CGEM from last week's top 10 showed very positive price action and it would be interesting to see the outcome of this week's pick.
0 · Reply
MaverikIT
MaverikIT Nov. 13 at 7:59 PM
$SLGL - well nice pop$
2 · Reply
weichsel1
weichsel1 Oct. 28 at 7:36 PM
$SLGL 104m current valuation is entirely supported by the 10 to 20m annual profit generated by approved and currently marketed products. (TWYNEO and EPSOLAY). The phase 3 SGT-610 and phase 2 SGT-210 are basically free...
0 · Reply
weichsel1
weichsel1 Oct. 28 at 7:20 PM
$SLGL Down 7 percent on a strongly up day for the market? Anything up? No news that I can see.
0 · Reply
MaverikIT
MaverikIT Oct. 21 at 4:01 PM
$PRAX $NERV $SLGL $AVTX $ARTC ...
0 · Reply
Jumpinjackflash33
Jumpinjackflash33 Oct. 15 at 2:31 PM
$SLGL warming up. $APLM
0 · Reply
Jumpinjackflash33
Jumpinjackflash33 Oct. 6 at 10:52 PM
$SPRB all out...last sale $210. See u tomorrow and keep an eye on $SLGL.
1 · Reply
Jumpinjackflash33
Jumpinjackflash33 Oct. 6 at 7:47 PM
$SPRB bidding $170....$SLGL next...humm.
0 · Reply